ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 33

B Cell Abnormalities in Patients with Chronic Cutaneous Lupus Erythematosus

Chungwen Wei1, Aisha Hill2, Kira Smith3, Ignacio Sanz1, S. Sam Lim4 and Cristina Drenkard4, 1Medicine, Emory University School of Medicine, Atlanta, GA, 2Medicine, Emory University School of Medicine, atlanta, GA, 3Emory University School of Medicine, Atlanta, GA, 4Division of Rheumatology, Emory University School of Medicine, Atlanta, GA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: B cells, cutaneous lupus erythematosus and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: B Cell Biology and Targets in Autoimmune Disease Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Lupus is a spectrum of disease with cutaneous lupus (CLE) without systemic features on one end and systemic lupus erythematosus (SLE) on the other. Among CLE subtypes, chronic cutaneous lupus (CCLE) is deemed less likely to be associated with systemic features. However, 10-20% CCLE will develop SLE throughout their disease course. Little is known regarding the immunological correlates to the disease progression, which we postulate may be accompanied by the emergence of SLE-associated B cell abnormalities. As an initial test for our hypothesis, we compared the B cell phenotypes in a cross-sectional analysis among patients with CCLE, SLE with or without CCLE.

Methods: Patients met SLICC and ACR criteria for the classification of CCLE and SLE. Frozen PBMCs were analyzed by flow cytometry from healthy controls (HC) (n=23) and patients with primary CCLE (n=60), SLE (n=58) or CCLE with SLE (n=42). B cell subsets were identified using the following markers: CD19, IgD, CD27, CD38, CD24, CD21, CD11c, 9G4, in addition to CD3 and live/dead staining as exclusion markers. Frequencies of the various B cell subsets were compared among the groups using ANOVA followed by Tukey’s multiple comparison statistical tests. To gain a global view of the changes in B cell homeostasis, an unsupervised hierarchical clustering analysis of the B cell profiles was carried out.

Results: Several B cell abnormalities have been shown in SLE patients compared to the healthy controls, including a contraction of IgD+CD27+ unswitched memory (USM) and an expansion of IgD–CD27– double negative (DN) cells. These observations are replicated in this study as well. Furthermore, within the DN population, a subset of cells with an activated phenotype (CD11c+CD21–, termed DN2) is significantly expanded in SLE compared to HC. Its counterpart in the IgD+CD27– naïve and transitional (N+T) compartment – the CD11c+CD21– activated naïve (aN) B cells – is also expanded in SLE, though not statistically different from HC. Interestingly, CCLE patients share with SLE the characteristic contraction of USM also seen in Sjogren’s and other autoimmune diseases, yet they do not exhibit the expansion of DN, activated DN2 and aN subsets. Instead, CCLE patients show an expansion of the early transitional (T1+T2) cells. Globally, an unsupervised hierarchical clustering analysis demonstrates the segregation of HC from SLE (with or without CCLE) on the basis of their B cell profiles. On the other hand, B cell profiles of CCLE patients are heterogeneous and interspersed between HC and SLE patients.

Conclusion: Cross-sectional analysis at baseline reveals that CCLE patients share some SLE abnormalities including contracted USM and expansion of early transitional B cells, but do not display expansions of activated mature B cells (both naïve and isotype switched DN cells), a phenotype that is frequently observed in SLE patients. Moreover, our study demonstrates that from a B cell standpoint, CCLE is a heterogeneous condition thereby opening the door to investigations of correlations between distinct B cell profiles and clinical variables and in particular, with progression to systemic disease. Confirmation awaits the longitudinal follow-up of these patients over the next years.


Disclosure: C. Wei, None; A. Hill, None; K. Smith, None; I. Sanz, None; S. S. Lim, None; C. Drenkard, None.

To cite this abstract in AMA style:

Wei C, Hill A, Smith K, Sanz I, Lim SS, Drenkard C. B Cell Abnormalities in Patients with Chronic Cutaneous Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/b-cell-abnormalities-in-patients-with-chronic-cutaneous-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/b-cell-abnormalities-in-patients-with-chronic-cutaneous-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology